Biodesix, Inc. (BDSX) 8-K Summary

This 8-K, dated November 3, 2025, announces the release of financial and operating results for the third quarter ended September 30, 2025.

• Item Triggered: Item 2.02.
• Key Disclosure: The detailed Q3 2025 earnings are furnished via Exhibit 99.1 (Press Release).
• Investor Action: Investors must review the attached press release for specific financial metrics (revenue, net loss, cash position, etc.).
• Status: The company confirms its status as an Emerging Growth Company.

Note: Information furnished under Item 2.02 is